We hypothesized that the deregulated activity of AML1, either a loss or gain of function, may represent one of the mechanisms for disease progression of CML, and set out to investigate expression levels of AML1 and its mutation in CML-BC for comparison with CML-CP clinical samples. The gene discussed is RUNX1; the disease is breast cancer.